Tecan Systems Handle High Throughput Prediction of Cancer Recurrence

Published: Aug 17, 2007

DURHAM, N.C.--(BUSINESS WIRE)--Researchers at the life sciences company Genomic Health Inc., California, have chosen Tecan’s liquid handling workstations to automate the development of their multi-gene expression assay that predicts the risk of recurrence of cancer and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients.

Back to news